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Sir,
We are very grateful to Shah et al, (2013) for their interest in our
review of ADT for prostate cancer. The aim of the review was to
highlight the spiralling costs of ADT and the likely increase in
adverse cardiovascular effects from the most commonly used forms
of ADT (LHrH analogues and orchidectomy) and in particular to
draw attention to the lack of research investigating which men are
at most risk and how to reduce such risk.
In this context, the PATCH study (Langley et al, 2013) is likely
to be a valuable addition to the literature, but may also represent a
missed opportunity. The ‘cardiovascular exclusion criteria’ for this
study are extensive. Thus, the results are not going to be
generalisable to all men with advanced prostate cancer being
considered for ADT, given the age range of the men affected and
the recognised association between prostate cancer mortality and
risk factors for cardiovascular disease, particularly obesity. The
initial study reported in this low-risk cohort was not powered to
detect a difference in cardiovascular events between the two groups
(LHrHa and oestrogen patches). However, Langley et al (2013)
report the incidence of cardiovascular events at a median follow-up
of 19 months (IQR 12–31, minimum 3 months) in the LHRHa
group as 7.1% (95% CI 2.7–14.9) and in the oestrogen-patches
group as 10.1% (95% CI 6.0–15.6). The number of events in
both groups seems rather high, with the rate of cardiovascular
events being 2.9% higher in the oestrogen-patch group than in the
LHRHa group (95% CI  4.2 to 10.1).
Whereas treatment with parenteral oestrogen may represent an
advance for certain adverse effects of ADT as well as possibly being
more cost-effective, evidence is still lacking. We stand by the
conclusion of our review, namely that a better understanding of the
risks and any excess treatment cost associated with ADT is
imperative to inform on the cost-effectiveness of various methods
of achieving castration and whether interventions are available to
reduce their risks. We hope the PATCH study will go some way
towards providing further evidence on cost-effectiveness, but are
disappointed it does not address cardiovascular risk in a
generalisable population.
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